Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD).